Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSI-7977 plus ribavirin versus pegylated interferon plus ribavirin in treatment-naive genotype 2 or 3 chronic hepatitis C
NL-OMON37539Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis C virus infection comparing PSI-7977 + ribavirin for 12 weeks with Pegylated interferon alfa + ribavirin for 24 weeks (2 arms). Primary endpoint: SVR12. Started Mar 2012; status: active, not recruiting.
02
Drugs
sofosbuvirribavirinpegylated interferon alpha
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON37539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37539.